

IR BOOK_(Finance)

THE INVESTOR RELATIONS OF CLASSYS 2025

13 Feb 2026

Disclaimer



This material has been prepared by Classys (the “company”) for the purpose of providing information in a presentation that will be made for investors. Please be informed that transferring, copying, or re-distributing this document to others is prohibited.

Attendance at this presentation is considered as your agreement to comply with the above-mentioned restrictions, and violation of these restrictions may be regarded as a violation of the Financial Investment Services and Capital Markets Act of South Korea.

The forward-looking statements included herein are unverified and pertains to future events related to the company’s expected future financial performance, and are expressed with words such as ‘forecast,’ ‘prospect,’ ‘expectation,’ ‘outlook’ and ‘(E).’ Despite being made in good faith based on reasonable grounds or assumptions by management, such “forward-looking statements” are subject to various influences, including changes in future business environments, and inherently contain uncertainties. As a result, actual future performance may significantly differ from the information stated or implied in the forward-looking statements. Additionally, the future outlook is based on the information available at the time of the presentation and is subject to change based on future market developments and changes in the Company’s strategic direction without prior notice.

The company and its executives do not assume any responsibility for losses incurred through the use of this document (including negligence and other cases).

This document does not constitute a solicitation for placement, sales, trading or subscription of stocks. No part of this document should be considered as a basis or ground for related contracts, agreements, or investment decisions. All investment decisions related to stock purchases should be made solely based on investors’ reasonable judgment.

Financial Results

- 4Q25 Review
- 2025 Review
- 2026 Guidance

1. Profit & Loss

(KRW bn)

consolidated basis	4Q25	4Q24	YoY	3Q25	QoQ
Revenue	93.4	74.4	+25.6%	83.0	+12.6%
COGS	(21.4)	(17.6)	+21.7%	(19.3)	+11.1%
(%)	22.9%	23.6%	-0.7%p	23.2%	-0.3%p
Gross profit	72.0	56.8	+26.8%	63.7	+13.0%
(%)	77.1%	76.4%	+0.7%p	76.8%	+0.3%p
SG&A	(20.8)	(21.0)	-0.9%	(26.1)	-20.2%
(%)	22.3%	28.2%	-5.9%p	31.5%	-9.2%p
Operating profit	51.2	35.8	+43.0%	37.6	+36.1%
(%)	54.8%	48.1%	+6.7%p	45.3%	+9.5%p
Financial Income	4.7	15.9	-70.7%	2.2	+107.9%
Financial Expenses	(0.9)	(0.9)	+1.3%	3.0	-131.2%
Other Income	0.3	0.0	+1411.5%	0.1	+369.6%
Other Expenses	(0.8)	(11.4)	-93.4%	(0.0)	+1410.5%
Pre-Tax Income	54.4	38.9	+39.9%	42.8	+27.1%
Tax Expenses	11.7	(10.2)	-215.1%	(9.7)	-220.5%
Net Income	42.6	28.7	+48.3%	33.1	+28.7%
(%)	45.6%	38.6%	+7.0%p	39.9%	+5.7%p
EBITDA	54.9	39.5	+39.0%	41.3	+32.8%
(%)	58.7%	53.1%	+5.7%p	49.8%	+8.9%p

2024	2025	YoY
242.9	336.8	38.6%
(51.8)	(75.7)	46.2%
21.3%	22.5%	1.2%p
191.1	261.1	36.6%
78.7%	77.5%	-1.2%p
(68.7)	(90.5)	31.7%
28.3%	26.9%	-1.4%p
122.4	170.6	39.3%
50.4%	50.7%	0.2%p
24.2	10.1	-58.4%
(6.2)	(10.8)	72.9%
0.0	0.4	1283.4%
(11.5)	(1.6)	-86.4%
127.9	168.7	31.9%
(30.1)	(13.3)	-55.8%
97.9	131.9	34.8%
40.3%	39.2%	-1.1%p
129.7	185.2	42.8%
53.4%	55.0%	1.6%p

- Revenue: KRW 93bn (YoY +25.6% QoQ 12.6%)**
 - First Quarter Above KRW 90 billion, 19 Consecutive YoY Growth Quarters, record high
 - 2025 Revenue recorded high at 336billion, +38% YoY
- Gross Profit: KRW 72bn (YoY +26.8%, QoQ +13.0%)**
 - Margin Expansion Despite Higher Device Mix Thanks to improved global standard production system
 - Device Mix : 4Q25 54%, 4Q24 51%, 3Q25 52%
 - Stable Margins Supported by Cost Optimization for Core products
 - Ilooda Revenue mix: 2024 3%, 2025 15%
- Operating Profit: KRW 51bn (YoY +43.1%, QoQ +36.2%)**
 - OP Surpassed KRW 50 Billion for the First Time
 - Quarterly Margin Improvement Driven by SG&A Discipline and Bad Debt Reversal
 - Full-Year OPM 50.8%, Industry leading Despite Ilooda Integration
- Profitability Ratios**
 - 4Q25
OPM 54.8% / NPM 45.6% / **EBITDA Margin 58.7%**
 - 2025
OPM 50.7% / NPM 39.2% / **EBITDA Margin 55.0%**

FX Rate

KRW/USD	4Q24	1Q25	2Q25	3Q25	4Q25
End	1,470	1,467	1,356	1,402	1,435
Avg	1,397	1,453	1,404	1,392	1,467

(Note 1) If negative or expenses, shown in parentheses

(Note 2) Net Income = attributable to owners of the parent company

2. Sales by Brand

(KRW bn)

consolidated basis	4Q25	4Q24	YoY	3Q25	QoQ
Revenue	93.4	74.4	+25.6%	83.0	+12.6%
Global	65.7	49.4	+33.1%	53.0	+24.1%
Korea	27.7	25.0	+10.6%	30.0	-7.8%
Device	50.5	38.1	+32.6%	42.9	+17.5%
Global	37.9	28.6	+32.9%	31.3	+21.1%
Korea	12.6	9.5	+31.8%	11.6	+7.9%
Consumables	41.1	34.7	+18.4%	37.3	+10.2%
Global	27.7	20.6	+34.9%	21.5	+28.7%
Korea	13.4	14.2	-5.5%	15.8	-15.1%
Homecare	1.6	1.4	+15.8%	2.5	-35.9%
Global	0.1	0.3	-70.3%	0.1	-31.6%
Korea	1.5	1.1	+36.5%	2.4	-36.2%
Rentals(Korea)	0.2	0.2	+7.8%	0.2	-2.9%

2024	2025	YoY
242.9	336.8	38.6%
163.6	224.7	37.3%
79.4	112.2	41.3%
123.9	174.0	40.4%
94.9	128.0	34.9%
29.0	45.9	58.4%
113.3	154.6	36.5%
67.0	95.5	42.5%
46.3	59.2	27.7%
4.7	7.3	54.5%
1.7	1.2	-32.1%
3.0	6.1	104.0%
1.0	0.9	-8.4%

- ❑ **Global: KRW 65bn (YoY +33.1%, QoQ +24.1%), 70% of Revenue**

 - Scale Market in EU and USA Device Growth → Installed Base Expansion
 - Asia Installed Base → Consumables Growth by Expanding Procedure Trends
 - Continued Recovery in Brazil
- ❑ **Korea: KRW 27bn (YoY +10.6%, QoQ -7.8%), 30% of Revenue**

 - Strengthened Market Position Through Expanding Shrink Universe and Volnewmer Brand Power
 - Revenue Contribution from Legacy Ilooda Portfolio
- ❑ **Devices: KRW 50bn (YoY +32.6%, QoQ +17.5%), 54% of Revenue**

 - Global Ultraformer Momentum & Volnewmer Scaling
 - Stable sales across Shurink Universe, Volnewmer, and laser portfolio
- ❑ **Consumables: KRW 41bn (YoY +18.4% QoQ +10.2%), 44% of Revenue**

 - Global Expansion in Ultraformer and Volnewmer Utilization
 - High Procedure Satisfaction Driving Strong Customer Loyalty
- ❑ **Homecare: KRW 1.6bn, 2% of Revenue**

 - Nov 28 Shrink Home Lift-to-Glow Launch

3. SG&A

(KRW bn)

consolidated basis	4Q25	4Q24	YoY	3Q25	QoQ
SG&A	20.8	21.0	-0.9%	26.1	-20.2%
(% of sales)	22.3%	28.2%		31.5%	
Salaries	3.9	3.7	+5.2%	4.1	-5.8%
(% of sales)	4.2%	5.0%		5.0%	
R&D	4.7	3.9	+19.6%	4.4	+7.6%
(% of sales)	5.0%	5.3%		5.2%	
Advertising	5.5	3.3	+63.4%	6.0	-8.9%
(% of sales)	5.8%	4.5%		7.2%	
Commissions	4.5	3.4	+34.6%	2.2	+108.2%
(% of sales)	4.8%	4.5%		2.6%	
D&A	2.8	2.7	+1.4%	2.8	-0.3%
(% of sales)	3.0%	3.7%		3.4%	
Sales commission	1.1	0.6	+84.6%	1.1	+0.4%
(% of sales)	1.2%	0.8%		1.4%	
Retirement benefits	0.3	0.2	+6.3%	0.3	+1.9%
(% of sales)	0.0%	0.0%		0.0%	
Others	(1.9)	3.1	-160.5%	5.3	-135.5%
(% of sales)	-2.0%	4.2%		6.4%	

2024	2025	YoY
68.7	90.5	31.7%
28.3%	26.9%	-1.4%p
12.5	15.7	25.4%
5.1%	4.6%	-0.5%p
12.6	17.4	38.2%
5.2%	5.2%	0.0%p
12.8	17.6	37.2%
5.3%	5.2%	-0.1%p
10.4	10.7	2.7%
4.3%	3.2%	-1.1%p
4.7	10.9	129.8%
2.0%	3.2%	1.3%p
3.4	5.6	63.0%
1.4%	1.7%	0.2%p
0.9	1.0	12.6%
0.0%	0.0%	0.0%p
11.3	11.6	3.1%
4.6%	3.5%	-1.2%

- ❑ **SG&A: KRW 20bn (YoY -0.9%, QoQ -20.2%), 22.3% of Revenue**
- ❑ **Salaries: KRW 3.9 bn YoY +5.2%, QoQ -5.8%), 4.2% of Revenue**
 - Headcount(end of period): 532(4Q25), 526 (3Q25) vs. 527 (4Q24),
- ❑ **R&D: KRW 4.7 bn (YoY +19.6%, QoQ +7.6%), 5.0% of Revenue**
 - R&D/Clinical Trials/Approval costs for new product and upgrade projects
- ❑ **Advertising: KRW 5.5 bn (YoY +63.4%, QoQ -8.9%), 5.8% of Revenue**
 - Annual spend within planned budget
- ❑ **Commissions: KRW 4.5 bn (YoY +34.6%, QoQ +108.2%), 4.8% of Revenue**
 - MedSystems acquisition related (4Q25)
- ❑ **Depreciation/Amortization: KRW 2.8 bn YoY +1.4%, QoQ -0.3%), 3.0% of Revenue**
 - Recurring amortization of merger-related assets
- ❑ **Others: KRW -1.9 bn (YoY -160%, QoQ -135%), -2.0% of Revenue**
 - the reversal of previously recognized bad debt provisions related to the AR

(Note 1) D&A = Depreciation/Amortization

4. Financial Position

(KRW bn)

consolidated basis	2022	2023	2024	4Q25
Assets				
Current assets	147.8	185.7	234.2	295.8
Cash & Cash Equivalents	111.6	136.9	158.0	207.6
Inventories	23.4	19.4	30.0	30.1
Accounts Receivables	6.9	17.3	36.9	48.4
Non-current assets	183.6	189.7	374.2	408.9
P.P.E	104.2	139.0	193.2	199.7
Investment Property	74.7	41.1	29.4	29.3
Intangible Assets	1.5	2.8	140.9	139.6
Total Assets	331.4	375.4	608.4	704.6
Liabilities				
Current liabilities	36.2	29.2	128.9	80.2
Non-Current liabilities	65.6	62.7	26.8	72.9
Total Liabilities	101.9	91.9	155.7	153.1
Equity				
Capital stock	6.5	6.5	6.6	6.6
Retained earnings	204.2	271.0	336.1	547.5
Total Equity	229.6	283.5	452.6	551.5
Total Liabilities+Equity	331.4	375.4	608.4	704.6

□ **Total Assets: KRW 704 bn**
Total Liabilities: KRW 153 bn/ Total Equity: KRW 551 bn

□ **Current Assets: KRW 295 bn**

- Cash & Cash Equivalents:
 - Up on strong operating performance
- Inventories:
 - Continued improvements in production management systems
- Accounts Receivable:
 - Revenue-driven increase in receivables remains well managed within normal aging and collection cycles.

□ **Non-current Assets: KRW 408 bn**

- PPE & Investment Properties:
 - HQ and plant buildings.
 - Integration Upon Completion of Former Irruda Industrial Facility
- Ongoing amortization of merger-related assets

□ **Current Liabilities: KRW 80bn**

- Short-Term Debt Converted to Long-Term

□ **Non-current Liabilities: KRW 72bn**

- HQ building loan: KRW 61 bn
- Increase from loan-financed installment payments for legacy ILOODA Knowledge Industry Center


(Note 1) Cash & Cash Equivalents is the sum of cash and cash equivalents, short-term financial instruments, and financial assets at fair value through profit or loss (FVPL).

Financial Results


- 4Q25 Review
- 2025 Review
- 2026 Guidance

1. IB Trends

Korea Installed Base(L) & Consumables Sales(R)




Ex-Korea Base(L) & Consumables Sales(R)



2. Market Portfolio


Sales by Region

(KRW bn)



Sales of Top 4 Countries


(KRW bn)



Financial Results

- 4Q25 Review
- 2025 Review
- 2026 Guidance

2026 Guidance



* Guidance Band : KRW 470 billion (yoy 40%) ~ KRW 510 billion (yoy 51%)

- 1 **Direct Operations in Brazil, LATAM and Japan: “Enhancing Profit Structure”**
 - Revenue recognition based on end-user pricing, with margin capture
 - Strengthened training and service, driving lock-in effects and accelerating market share expansion
- 2 **US & Europe: “Scaled Growth”**
 - Accelerating adoption across key European markets
 - Expanding RF leadership in the U.S. with Quadessy and Everesse, expecting 2027 Ultraformer approval
- 3 **Volnewmer(Everesse): “Next Global Flagship”**
 - Entering a high-growth trajectory with annual unit sales exceeding 2,000
 - Positioned as the next Flagship succeeding Ultraformer, which surpasses 3,000 units annually
- 4 **Quadessy, Laser: “Next Gen. MNRF, First kind of Laser”**
 - Aiming to surpass 1,000 units annually as global rollout progresses
 - Establishing Quadessy as a primary expansion driver in the MNRF category
- 5 **Korea: “Leading the Combined-Procedure Trend”**
 - Combination procedure strategy across Volnewmer, Shrink Universe, and Fortra
 - Accelerating procedure volume growth and utilization rates
- 6 **Home Beauty: “B2C Revenue Leverage”**
 - Broadening retail and distribution footprint for Shrink Home Lift-to-Glow
 - Enhancing B2C revenue contribution through continued portfolio expansion
- 7 **China: “Market Entry”**
 - Distributor agreement; commercial rollout expected upon Volnewmer approval
 - Positioned as a strategic long-term growth opportunity with Ultraformer



208, Teheran-ro, Gangnam-gu, Seoul

<http://www.classys.com> | +82-2-6313-2106

email: ir@classys.com